Arca
Skip to content
Tools
Tools

IDH2: Isocitrate dehydrogenase [NADP], mitochondrial

Plays a role in intermediary metabolism and energy production.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on IDH2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Enasidenib
  • Vorasidenib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        EnasidenibBoxed warningApprovedBristol-Myers SquibbSmall moleculeInhibitorIsocitrate dehydrogenase [NADP], mitochondrial inhibitor25
        VorasidenibApprovedServierSmall moleculeInhibitorIsocitrate dehydrogenase [NADP], mitochondrial inhibitor19

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
        A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.VorasidenibPhase 3Not yet recruitingInstitut de Recherches Internationales ServierNov 17, 2026
        Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic CholangiocarcinomaVorasidenibPhase 2Not yet recruitingM.D. Anderson Cancer CenterNov 16, 2026
        A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)VorasidenibPhase 1Not yet recruitingHeidelberg UniversityOct 16, 2026
        Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseVorasidenibPhase 2RecruitingNuvation Bio Inc.Jul 14, 2026
        VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 MutationsVorasidenibPhase 1Not yet recruitingMegan ManticaJun 5, 2026
        Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy ComparedVorasidenib—RecruitingFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaApr 23, 2026
        Vorasidenib Guided by AGX PET in Recurrent/Low-grade GliomaVorasidenibNot applicableNot yet recruitingHuashan HospitalMar 13, 2026
        Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationVorasidenibPhase 2RecruitingInstitut de Recherches Internationales Servier (I.R.I.S.)Dec 16, 2025
        A Study of Enasidenib in People With T-Cell LymphomaEnasidenibPhase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterJan 2, 2025
        Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)EnasidenibPhase 2RecruitingNational Cancer Institute (NCI)Nov 4, 2024
        Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)EnasidenibPhase 2RecruitingNational Cancer Institute (NCI)Aug 29, 2024
        Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized TrialEnasidenibPhase 2RecruitingWashington University School of MedicineFeb 5, 2024
        Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsEnasidenibPhase 2RecruitingNational Cancer Institute (NCI)Dec 20, 2023
        A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)EnasidenibPhase 1Active, not recruitingMemorial Sloan Kettering Cancer CenterMar 6, 2023
        MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)EnasidenibPhase 2RecruitingNational Cancer Institute (NCI)Oct 3, 2022
        IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)EnasidenibPhase 2RecruitingAlice MimsJun 2, 2022

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        D-2-hydroxyglutaric aciduria
        0.76
        Glioma
        0.72
        2-hydroxyglutaric aciduria
        0.54
        Myeloid neoplasm
        0.49
        Maffucci syndrome
        0.44
        Ollier disease
        0.41
        Hereditary disease
        0.41

        Genes and related targets

        Complexes and families that share a gene with this target
        Genes
        IDH2
        Related
        IDH1/IDH2

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3991501, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P48735, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.